In April 2015 Carbylan Therapeutics, Inc., merged with KalVista Pharmaceuticals forming a combined company focused on discovering, developing, and commercializing plasma kallikrein inhibitors for the treatment of hereditary angioedema (HAE) and diabetic macular edema (DME). The merged firm continued to trade on NASDAQ until original cal letters.Formerly doing business as Sentrx Surgical and as Carbylan BioSurgery Inc, is an emerging medical device company using proprietary modified biopolymers to create synthetic scaffolds that mimic the normal extracellular matrix. This synthetic scaffold can be used to promote scar-free wound healing, engineer new tissues, and prevent post-surgical adhesions. Carbylan is developing bioresponsive medical products for osteoarthritis. to develop and market medical devices and device/drug combination products based on chemically engineered polymers of hyaluronic acid, a well known polysaccharide widely present in the human body. Its initial market focus is therapeutic medical devices for rhinosinusitis and osteoarthritis. Carbylan's proprietary technology enables delivery of biomaterial-based medical devices as injectable liquids that self-polymerize inside the body to form therapeutic implants that covalently bind to tissues at the target delivery site.
